| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3283193 | Clinical Gastroenterology and Hepatology | 2011 | 6 Pages |
Abstract
Radiologic improvement was observed in 63.4% of patients with Crohn's disease who received infliximab therapy, despite a study design that was likely biased toward nonresponders. Radiologic response was not in good agreement with clinical symptoms, serum biomarkers, or endoscopic appearance; CTE might be used as a complementary approach to identify mural healing or inflammation not detected by other methods.
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
David H. Bruining, Edward V. Jr, Eric C. Ehman, Hassan A. Siddiki, Douglas L. Nguyen, Jeff L. Fidler, James E. Huprich, Jayawant N. Mandrekar, William S. Harmsen, William J. Sandborn, Joel G. Fletcher,